 BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF announced that it has obtained positive results from an in vivo oral bioavailability and food-effect pharmacokinetic PK study on BETR-001 in beagle dogs. BETR-001 is a non-hallucinogenic derivative of lysergic acid diethylamide LSD, the company said. 